Immunomedics initiated with an Overweight at Piper JaffrayPiper Jaffray analyst Joseph Catanzaro started Immunomedics with an Overweight rating and $33 price target, stating that he believes its Phase 2 data in triple negative breast cancer "fully support" an accelerated U.S. approval. He could see robust adoption in this setting leading to U.S. sales over $1B by 2028, Catanzaro tells investors. Sacituzumab has reported "impressive" data in both urothelial bladder cancer and ER+/HER2- breast cancer, which could also be "blockbuster opportunities," the analyst added.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. * $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.